Carlo Besta Neurological Institute

InFlectis BioScience Awarded $943,000 Grant from the ALS Association to Advance Ongoing ALS Clinical Trial with the Support of IRCCS Carlo Besta Neurological Institute

Retrieved on: 
수요일, 1월 3, 2024
ALS, Carlo Besta Neurological Institute, INN, Trial of the century, IRCCS, ALS Association, Biomarker, Oxidative stress, NMDAR, Patient, Pharmaceutical industry

The trial is investigating IFB-088 (INN: icerguastat), a multifunctional drug that modulates the PPP1R15A/PP1c phosphatase complex and inhibits NR2B-containing NMDAR.

Key Points: 
  • The trial is investigating IFB-088 (INN: icerguastat), a multifunctional drug that modulates the PPP1R15A/PP1c phosphatase complex and inhibits NR2B-containing NMDAR.
  • The potential of IFB-088 lies in its ability to target three major ALS cellular pathophysiological mechanisms to manage disease progression: protein aggregation, oxidative stress, and glutamate excitotoxicity.
  • InFlectis Bioscience has been awarded a $943K grant from the ALS Association to support the recruitment of 50 patients by the end of January 2024 for its Phase 2 clinical trial evaluating IFB-088.
  • The grant also supports a multi-omics approach, conducted by the IRCCS "Carlo Besta" Neurological Institute in Milan, Italy to investigate pharmacodynamic biomarker candidates, which will be useful in a future pivotal clinical study.